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Type I interferons (IFN-I) were identified over 50 years ago as cytokines critical for host
defense against viral infections. IFN-I promote anti-viral defense through two main mecha-
nisms. First, IFN-I directly reinforce or induce de novo in potentially all cells the expression
of effector molecules of intrinsic anti-viral immunity. Second, IFN-I orchestrate innate and
adaptive anti-viral immunity. However, IFN-I responses can be deleterious for the host
in a number of circumstances, including secondary bacterial or fungal infections, several
autoimmune diseases, and, paradoxically, certain chronic viral infections. We will review
the proposed nature of protective versus deleterious IFN-I responses in selected diseases.
Emphasis will be put on the potentially deleterious functions of IFN-I in human immunod-
eficiency virus type 1 (HIV-1) infection, and on the respective roles of IFN-I and IFN-III in
promoting resolution of hepatitis C virus (HCV) infection. We will then discuss how the
balance between beneficial versus deleterious IFN-I responses is modulated by several
key parameters including (i) the subtypes and dose of IFN-I produced, (ii) the cell types
affected by IFN-I, and (iii) the source and timing of IFN-I production. Finally, we will specu-
late how integration of this knowledge combined with advanced biochemical manipulation
of the activity of the cytokines should allow designing innovative immunotherapeutic treat-
ments in patients. Specifically, we will discuss how induction or blockade of specific IFN-I
responses in targeted cell types could promote the beneficial functions of IFN-I and/or
dampen their deleterious effects, in a manner adapted to each disease.
Keywords: type I interferons, dendritic cells, chronic viral infections, immunotherapy, bioengineering
INTRODUCTION
Type I interferons (IFN-I) were the first cytokines discovered,
over 50 years ago, based on their potent anti-viral effects (1, 2).
IFN-I play a crucial, non-redundant role in vertebrate anti-viral
defenses (3–5). IFN-I also mediate protective effects in other phys-
iopathological contexts, including cancer (6) and multiple sclerosis
(MS) (7). On the contrary, IFN-I responses can be deleterious in
a number of circumstances, including bacterial or fungal infec-
tions (8–10), many autoimmune diseases (11), and, paradoxically,
certain chronic viral infections (12–14). It is only recently that
an integrated picture has emerged of the cellular and molecular
mechanisms regulating the production of IFN-I and underlying
their functions. Much knowledge was gained recently on another
class of potent innate anti-viral interferons, the lambda, or type
III IFNs (IFN-III). We will review knowledge on IFN-I/III (IFNs)
and discuss how it could be harnessed to develop innovative ther-
apeutic strategies aimed at surgically tuning IFN activity toward
protective responses in a manner adapted to each disease. We
will focus on IFN-α/β/λ because they are the best characterized
IFNs and already used therapeutically. Recent reviews are cover-
ing information on other IFN-I subsets including IFN-ε, which is
produced at mucosal sites and promotes local anti-viral defenses
(15, 16).
Dendritic cells (DCs) are rare heterogeneous mononuclear
phagocytes functionally characterized by their unique efficacy
for antigen-specific activation of naïve T lymphocytes. DCs are
sentinel cells of the immune system, able to sense and inte-
grate a variety of danger input signals for delivery of output
signals instructing the activation and functional polarization
of effector immune cells. In mammals, five major DC sub-
sets exist, which differ in their expression of innate immune
recognition receptors (I2R2s) and in their functional special-
ization: monocyte-derived DCs (MoDCs), Langerhans cells,
CD11b+ DCs, XCR1+ DCs, and plasmacytoid DCs (pDCs) (17).
A recurrent theme of this review will be the intricate rela-
tionships between IFNs and DCs, since these cells can be a
major source and/or target of these cytokines under various
conditions.
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The first section will synthesize current knowledge on IFN
production and protective anti-viral functions. The I2R2s and
downstream signaling pathways responsible for IFN-I production
during viral infection will be listed. The roles of different cell types
for this function will be discussed. The two main mechanisms
through which IFN-I promote anti-viral defense will be reviewed,
succinctly for direct anti-viral effects and in greater details for
immunoregulatory functions.
The second section will focus on the detrimental functions of
IFN-I. Selected diseases will be discussed to illustrate how differ-
ent, and sometimes opposite, processes underlie deleterious IFN-I
responses depending on the physiopathological contexts. IFN-I
induction of unbridled inflammatory responses causing lethal tis-
sue damage will be discussed as a major pathological mechanism
during bacterial encounters secondary to influenza infection or in
some autoimmune diseases. Inappropriate functional polarization
of immune responses by IFN-I will be discussed as one potential
cause for enhanced susceptibility to bacterial or fungal infections.
The complex and disputed role of IFN-I in chronic viral infec-
tions will be reviewed, with emphasis on the physiopathology of
the infections by human immunodeficiency virus type 1 (HIV-
1) and human hepatitis C virus (HCV), with an outlook for the
development of novel immunotherapeutic strategies to combine
with anti-viral drugs.
The third section will recapitulate how the balance between
beneficial versus deleterious IFN-I responses is modulated by sev-
eral key parameters including (i) the source and timing of IFN-I
production, (ii) the cell types affected by IFN-I, and (iii) the
signaling pathways activated by IFN-I.
In the last section, we will speculate how integration of all the
knowledge discussed before combined with advanced biochem-
ical manipulation of the activity of the cytokines should allow
designing innovative immunotherapeutic treatments, based on
induction or blockade of specific IFN-I responses in targeted cell
types. This“activity-by-targeting”concept is based on the design of
novel “immuno-IFNs” consisting in covalent association between
a mutated IFN-I with decreased affinity for its receptor and an
antibody with high avidity for a molecule specifically expressed
on target cell types (18). This design ensures lack of activity of
the immuno-IFNs on all cell types but those targeted, contrary
to previous strategies using IFNs with close to maximal potency
that were still able to mediate strong off-target effects despite their
coupling to cell-type specific antibodies and/or their local delivery.
GENERAL CONCEPTS ON IFN PRODUCTION AND FUNCTIONS
HOW IS THE PRODUCTION OF IFN CONTROLLED?
Type I interferons expression is not detectable under steady state
conditions in vivo using classical methods such as gene expression
analysis by RT-PCR or protein titration by ELISA or bioassays.
However, mice deficient for the expression of the alpha chain of
the IFN-I receptor (IFNAR1) harbor alteration in the ontogeny
or functions of various cell types (19–26). Hence, extremely small
or localized but functionally relevant quantities of IFN-I must
be produced under steady state conditions (27). Indeed, the exis-
tence of steady state responses to IFN-I in various organs in vivo
was demonstrated by using reporter mice expressing the firefly
luciferase under the control of the promoter of Ifnb1 (28) or
of Mx2 (29), a canonical IFN-I-stimulated gene (ISG). Steady
state IFN-I responses are promoted by gut commensals (30).
Early and transiently after many viral infections, large amounts
of IFNs can be detected, in blood and spleen in the case of sys-
temic infections or locally in the case of confined infections. IFN
induction during viral infections results from the detection of
specific danger signals by specialized I2R2s. This includes the
detection of pathogen-associated molecular patterns as well as
the sensing of stress signals or damage-associated molecular pat-
terns (31, 32). Based on the nature and intracellular location of
the danger signals that induce the production of the cytokines,
the cellular sources of IFNs during viral infection can be classi-
fied in two main groups. Infected cells often contribute to IFN
production as a response to their sensing of endogenous viral
replication, or consecutive to the metabolic stress induced during
massive translation of viral structural proteins, or as a result of
plasma membrane perturbations upon viral entry. Specific sub-
sets of uninfected cells can also significantly contribute to IFN
production upon engulfment of material containing viral-derived
nucleotide sequences and sensing of these molecules in endosomes
by specific I2R2s. All sensing pathways leading to IFN induction
converge on the activation of interferon response factors 3 or 7
(IRF3/7), which are the master transcription factors inducing IFN
genes. Most cell types constitutively express IRF3 but not IRF7
or only at low levels. IRF7 expression requires IFN-I stimula-
tion. IFN-β can directly be induced by IRF3. All but one of the
IFN-α subtypes require IRF7 for their induction. Hence, IFN-β
secretion promotes its own production and that of IFN-α in an
autocrine manner (33, 34). This positive feedback loop strongly
amplifies IFN production during viral infections, promoting fast
and widespread induction of cell-intrinsic anti-viral defenses in
uninfected cells to prevent virus dissemination. Other feedback
loops tightly regulate IFN-I production positively or negatively.
This section reviews different mechanisms controlling IFN pro-
duction and how they could play different roles in host/virus
interactions.
IFN production in infected cells is initiated by sensing of
endogenous viral replication
Plasma membrane modifications occur upon virus entry which
can induce IFN-I production and ISGs through a STING-
dependent signaling. Infected cells can sense abnormal changes
in the physical or biochemical properties of their plasma mem-
brane upon virus entry, which can trigger their production of
IFN-I (35, 36). This event depends on signaling by the endoplas-
mic reticulum (ER) – resident transmembrane protein stimulator
of interferon genes (STING). Upon virus entry, STING translo-
cates to the cytosol where it is activated by phosphatidylinositol
3-kinase (PI3K) and calcium-dependent pathways to initiate a sig-
naling cascade leading to IRF3-dependent induction of IFN-I and
ISGs (Figure 1) (31, 37).
Viral nucleotide sequences are sensed by dedicated I2R2s in the
cytosol of infected cells, which induces IFN-I production. Some
I2R2s are located in the cytosol and bind viral nucleotide sequences
to induce IFN-I production in infected cells. These I2R2s are
classified as cytosolic RNA or DNA sensors. Their specificity for
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FIGURE 1 | A simplified model of the potential contributions of selective
sensors and cell types to IFN production during viral infections. Different
innate immune recognition receptors are involved in sensing various types of
viral nucleic acids in distinct categories of cells during viral infections, which
may promote different types of anti-viral defenses. For each selected sensor
shown, the types of viral nucleic acids recognized and the downstream
signaling cascade induced are represented in a simplified, schematic manner.
The potential specific role of each cell type in anti-viral defenses is also
indicated at the bottom of each panel. (A) Potentially all types of infected cells
can detect endogenous viral replication through cytosolic sensors triggering
their local production of IFN-β/λ to control viral replication in an autocrine and
paracrine fashion in infected tissues. (B) Uninfected XCR1+ DCs selectively
produce high levels of IFN-λ and IFN-β upon engulfment of materials
containing dsRNA and the consecutive triggering of TLR3 in endosomes. The
receptor of IFN-λ is mostly expressed by epithelial cells. Hence, XCR1+ DCs
might be involved in inducing local IFN responses in virally infected epithelial
tissues. Since XCR1+ DCs are especially efficient at producing IFN-III upon
HCV stimulation, they might contribute to local or systemic IFN production
during infection with this virus, to promote IFN-λ-mediated protection of
hepatocytes. Uninfected XCR1+ DCs and other uninfected cells may produce
some IFN-β upon engulfment of materials containing ssRNA and the
consecutive triggering of TLR8 in endosomes. The contribution of this
pathway to anti-viral defense is not well understood yet, in part because
mouse TLR8 is deficient for this function. (C) Uninfected pDCs selectively
produce high levels of all subsets of IFNs upon engulfment of materials
containing ssRNA or CpG DNA and the consecutive triggering of TLR7/9 in
endosomes. However, pDCs seem to be activated for this function only in
lymphoid tissues. Hence, pDC might contribute to systemic IFN production
during blood-borne viral infections or as a failsafe mechanism activated upon
abnormal widespread dissemination of a viral infection once it has escaped
local confinement at its portal of entry. CM, cell membrane; NM, nuclear
membrane.
particular nucleotide sequences or tertiary structures, their sig-
naling pathways and their physiological significance have been
recently reviewed (31, 32). Cytosolic RNA sensors encompass
DExD/H helicases among which the retinoic-acid-inducible gene
(RIG)-I-like receptors (RLRs) have been the most studied, namely
RIG-I and melanoma differentiation associated gene 5 (MDA5).
RIG-I recognizes RNA with a 5′-PPP or 5′-PP (38) (uncapped)
moiety, or double-stranded RNA (dsRNA), both structures being
present in viral, but not in cytosolic eukaryotic, RNA molecules.
MDA5 might specifically recognize long dsRNA fragments. Both
RIG-I and MDA5 contain a DexD/H box-containing RNA heli-
case domain, and 2 caspase recruitment domains (CARD1/2),
which bind to mitochondrial anti-viral signaling protein (MAVS).
RNA/RLR/STING molecular complexes initiate a signaling cas-
cade leading to IRF3/7-dependent induction of IFNs (Figure 1).
Other DExD/H helicases can promote IFN-I production in DCs,
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although their physiological roles for in vivo immune defenses
against viral infections remain to be established (32). Cytosolic
DNA sensors able to induce IFN-I (mostly IFN-β) and IFN-
III encompass molecules belonging to different protein fami-
lies, including DExD/H helicases, the inflammasome component
IFN-γ-inducible protein 16 (IFI16), the Z-DNA binding pro-
tein 1 (ZBP1), and the cyclic GMP-AMP (cGAMP) synthase
(cGAS) (31, 32). Most of the cytosolic DNA sensors activate
STING and lead to IRF3/7- and NFκB-dependent induction of
IFN-β and IFN-III. Many cell types express ZBP1 and are able
to produce IFN-I upon triggering of this molecule, including
macrophages, DCs, and fibroblasts following an HSV-1 infection
(39, 40). Upon DNA binding, cGAS catalyzes the production of
cGAMP. cGAS is critical for the detection of lentiviruses including
HIV-1/2 (41, 42) and can contribute to sensing of, and protec-
tion against, other RNA viruses, including in vivo in mice (43).
cGAMP also acts as a secreted second messenger signal alerting
uninfected cells to directly induce their expression of intrinsic
immune anti-viral defenses. The cGAS/STING/IRF3 signaling cas-
cade and the IRF1 transcription factor are “master” inducers of
cell-intrinsic immunity able to control the replication of most
DNA and some RNA viruses at least in part independently of
IFNs (43).
Viral hijacking of the protein synthesis apparatus of the host cell
triggers ER overload, a stress, which synergizes with cytosolic
sensing to promote IFN-I production. Infected cells become a
factory for production of viral particles. Hijacking of the trans-
lation apparatus of the host cell for massive production of viral
structural proteins leads to an overload of the capacity of the ER
for correct folding of newly synthesized proteins. ER overload
induces a homeostatic response of the cell, the unfolded protein
response (UPR). UPR aims at restoring normal ER functions by
inhibiting translation. UPR activation in infected cells contributes
to prevent viral replication, including through inhibition of the
production of viral proteins, promotion of IFN-I production, and
induction of cell suicide (44).
IFN-I production in uninfected cells is initiated by endosomal
sensing of viral nucleotide sequences derived from engulfed virions
or infected cells
Toll-like receptors (TLRs) are among the first and best character-
ized I2R2s. TLRs are transmembrane proteins with a leucine-rich
repeat extracellular domain involved in ligand recognition and
an intracellular toll/interleukin-1 receptor domain essential for
signaling (45). Among the nine TLRs conserved between mouse
and human, TLR3, TLR7, TLR8, and TLR9 are located in endo-
somes where they can detect the abnormal presence of nucleic
acids such as occurs upon endocytosis of virions or of virally
infected cell material. TLR3 recognizes dsRNA, TLR7/8 ssRNA,
and TLR9 DNA sequences containing unmethylated cytidine-
phosphate-guanosine (CpG) motifs. TLR fine specificity and sig-
naling pathways have been reviewed recently (32) and are sum-
marized in Figure 1. We will discuss the expression patterns
and functions of endosomal TLRs with regards to IFN pro-
duction in uninfected specialized immune cell types, pDCs and
XCR1+ DCs.
Selective expression of TLR7, TLR9, and IRF7 in pDCs endows
them with a unique ability to produce very high amounts of
all subtypes of IFNs upon virus stimulation irrespective of their
own infection. Plasmacytoid DCs uniquely produce very large
amounts of IFNs in response to in vitro stimulation with many
viruses, without being infected (46). IFN-I mRNAs represent up
to 40% of all mRNAs in pDCs at the peak of their activation (47).
In vitro, upon exposure to influenza virus, herpes virus type 1,
cytomegaloviruses, or vesicular stomatitis virus, individual pDCs
produce 100–1000 times more IFNs than total PBMCs, monocytes,
MoDCs, cDCs, neutrophils, and fibroblasts (47–52). However,
in vitro, high molarity infection of cDCs with certain viruses
unable to inhibit IFN-I production in their target cells can also
induce massive IFN-β secretion (53). pDCs produce high levels of
all subtypes of IFNs, contrary to many other cell types including
infected cells, which often preferentially produce IFN-β (46, 47).
In vivo, pDC depletion during systemic viral infections leads to
over 95% decrease of IFN-I production, while the total number of
pDCs producing IFN-I (<100,000 in one mouse) is much lower
than the total number of infected cells (54–59). This shows that
in vivo also individual activated pDCs produce much more IFN-
I/III than most other cell types, including virus-infected cells. The
professional IFN-producing function of pDCs largely results from
their high constitutive and selective expression of IRF7, TLR7, and
TLR9 (Figure 1). These molecules are pre-associated in ready-
to-signal complexes located in specialized endosomes specific to
pDCs (60, 61). pDCs must also be equipped for efficient sensing
and up-take of virions and virus-infected cells. The corresponding
cell surface I2R2s remain to be identified.
Selective expression of TLR3 in XCR1+ DC endows them with
a unique ability to produce very high amounts of IFN-β and
IFN-III upon stimulation with dsRNA or HCV irrespective of
their own infection. XCR1+ DCs are very potent for antigen-
specific activation of CD8+ T cells, in particular through cross-
presentation of exogenous antigens that they have captured from
other cells and processed for association with class I major com-
plex histocompatibility (MHC-I) molecules (62). In mice, XCR1+
DCs are crucial for the initiation of protective adaptive immune
responses against tumors and a variety of viruses (63). Mouse and
human XCR1+ DCs constitutively and selectively express high
levels of TLR3 (Figure 1). They produce large amounts of IFN-III
and IFN-β upon stimulation with a synthetic mimetic of dsRNA,
Polyinosinic:polycytidylic acid (PolyI:C) (64, 65). Human XCR1+
DCs uniquely respond to stimulation with HCV by producing
large amounts of IFN-III in a TLR3-dependent manner (66, 67),
irrespective of their own infection.
Positive and negative feedback loops regulating IFN-I production
Positive feedback loops. In addition to IRF7 induction, other
positive feedback mechanisms exist to amplify the production
of IFNs rapidly after initiation of a viral infection as illustrated
by the following selected examples. IFNs induce the expression
of many cytosolic RNA/DNA sensors and of TLR7. This broad-
ens the spectrum of host’s cell types able to detect endogenous
viral replication for IFN induction. Induction of OASL by IFNs in
human cells enforces RIG-I signaling, counteracting viral immune
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evasion genes interfering with this sensing pathway (68). The IFN-
inducible ribonuclease L (RNaseL) generates viral and cellular
RNA degradation products, which engage RLRs for amplification
of IFN production (69, 70). The IFN-inducible Protein kinase R
(PKR) stabilizes IFN-I mRNA (71).
Negative feedback loops. To prevent unbridled responses delete-
rious for the host, IFN activity must be tightly controlled including
during viral infections. Several negative feedback loops exist to
terminate IFN production, after anti-viral defenses have been acti-
vated. The ISG ubiquitin specific peptidase 18 (USP18) binds
to IFNAR2, preventing it from recruiting signal transducer and
activator of transcription 1 (STAT1). IFNs induce the expres-
sion of TAM receptor tyrosine kinases in DCs, monocytes, and
macrophages. TAM receptors associate and signal in part through
IFNAR1. They activate the suppressors of cytokine signaling-1/3
(SOCS-1/3). SOCS inhibit TLR and RLR signaling, thereby ter-
minating IFN production (72). TAM receptor ligands, Gas6 and
ProS, bind phosphatidylserine on dying cells and are produced by
activated DCs and monocytes/macrophages. Thus, IFN induction
of TAM inhibitory receptors on uninfected phagocytic immune
cells could limit their propensity to produce the cytokines upon
engulfment of dying virally infected cells. IFNs induce Tetherin on
most cell types. pDCs express a receptor for Tetherin, leukocyte
immunoglobulin-like receptor, subfamily A (with TM domain),
member 4 (LILRA4). LILRA4 triggering on pDCs inhibits their
production of IFN-I. Hence, through LILRA4 engagement by
Tetherin, pDCs can monitor their efficacy at inducing an anti-
viral gene expression program in neighboring cells through IFNs,
and timely terminate their IFN production.
How positive and negative feedback loops integrate in time and
space to promote optimal kinetics and intensity of IFN produc-
tion in order to efficiently control viral infection without causing
severe immunopathology is not completely understood. Positive
feedback loops may occur very rapidly after initiation of viral
infection to allow rapid secretion of high levels of the cytokines
for fast and strong induction of anti-viral cell-intrinsic immu-
nity. Negative feedback loops occur likely later to terminate the
response and thus avoid chronicity of cytokine production and its
ensuing deleterious effects.
What are the respective roles of infected versus uninfected cells in
IFN production during viral infections?
IFN production by infected cells serves as first line of defense to
block viral replication at his portal of entry in the body, while
IFN production by uninfected pDCs might constitute a failsafe
mechanism activated only when viral infection gets systemic.
pDCs do not constitute the major source of IFN production upon
local infections by several viruses in the lung or in the female
reproductive tract. pDCs are dispensable for resistance against
these infections (56, 73, 74). During pulmonary infection by New-
castle disease virus (NDV), IFN-I are produced locally in the
lungs mainly by infected alveolar macrophages. Lung pDCs do
not express the cytokines (73). Selective depletion of lung alveo-
lar macrophages leads to systemic dissemination of NDV, and to
a strong activation of pDCs for IFN-I production specifically in
the spleen. Even in the case of systemic viral infections such as
caused by intravenous injection of NDV or intraperitoneal injec-
tion of mouse cytomegalovirus (MCMV), pDC IFN production
is confined to the spleen. It is not detected in other organs even
those with high viral replication (59, 73). Hence, splenic pDCs
are especially prone to high level IFN production upon systemic
acute viral infections. pDCs located in non-lymphoid organs, in
particular mucosal barrier tissues, appear to be inhibited for IFN
production. Thus, IFN production by infected cells serves as first
line of defense to block virus replication at its portal of entry in
the body. IFN production by uninfected pDCs might constitute
a failsafe mechanism mainly activated in the spleen when viral
infection gets systemic (75). Under these conditions, to promote
health over disease, the benefits for the host of producing high cir-
culating levels of IFNs in order to induce widespread cell-intrinsic
anti-viral defenses might prevail over the deleterious effects that
this could cause on certain cell types or tissues. Indeed, pDCs are
required for protection against HSV-2 and HSV-1 in mice only in
systemic but not local infections (56). This observation is consis-
tent with the crucial role of pDCs for protection of mice against
systemic infection by mouse hepatitis virus (MHV), a fast repli-
cating coronavirus (55). Conflicting results have been obtained on
the role of pDCs during intranasal influenza infection (74, 76–78).
A possible explanation is that pDC IFN production contributes to
resistance to highly pathogenic influenza strains that might sys-
temically spread from the lung early after infection, even if at low
levels. Another intriguing observation is that IFNs are critical for
host resistance to MCMV and that pDCs are the major source
of IFNs in this infection model but are dispensable for virus con-
trol (54). Studies are ongoing to understand this apparent paradox.
Patients bearing genetic mutations disrupting endosomal TLR sig-
naling do not appear to suffer from life-threatening viral infections
(79, 80), contrary to patients impaired in IFNAR signaling (4, 81).
A notable exception is the specific susceptibility to severe herpes
virus encephalitis in individuals’ deficient for TLR3 signaling (82,
83). However, contrary to extracellular TLR, endosomal TLR have
evolved under strong purifying selection in human beings (84).
Hence, while pDCs and endosomal TLR might have been required
for protection of our species against viral infections in the past,
this appears not to be the case anymore perhaps due to improved
social, hygiene, and health care in modern society (75).
IFN production by uninfected pDCs or XCR1+ DCs might pro-
mote protection against viruses able to interfere with the sig-
naling pathways inducing cytokine production in infected cells.
Attesting to the importance of IFNs for anti-viral defense in
vertebrates, many mammalian viruses encode immune evasion
genes specifically inhibiting the production of IFNs in infected
cells (39, 85). pDCs or XCR1+ DCs might be essential for IFN-
dependent host protection against these viruses, because they are
spared from the intracellular functions of viral immune evasion
genes (75). To the best of our knowledge, MCMV does not encode
for immune evasion genes inhibiting IFN production. However,
MCMV manipulates IFN-I responses through specific inhibition
of STAT1 functions in infected cells. Thus, pDCs might be dis-
pensable for resistance against systemic MCMV infection due to
sufficient levels of IFN production by infected cells locally in all
infected tissues. Hepatocyte responses to IFN-III appear to play a
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critical role in human resistance to HCV. In infected hepatocytes,
HCV induces the expression of cellular microRNAs binding to
IFN-III mRNA and leading to its degradation. Uninfected XCR1+
DCs produce high levels of IFN-III in vitro upon HCV stimula-
tion (66, 67). Hence, during acute HCV infection in vivo, XCR1+
DC may be a strong and early source of IFN-III not subjected to
virus immune evasion strategies, therefore, contributing to protect
naturally resistant individuals.
Altruistic suicide of subcapsular sinus macrophages in secondary
lymphoid organs promotes strong IFN responses to control
viral dissemination. In secondary lymphoid organs, a subset
of macrophages is critical for the clearance of viruses from the
lymph (86). These macrophages are located on viral entry routes,
near to subcapsular sinuses where the afferent lymph drained
from non-lymphoid tissues flows. Contrary to other subsets of
macrophages, subcapsular sinus macrophages are highly suscepti-
ble to viral infection, because they constitutively express only low
levels of effector molecules of cell-intrinsic anti-viral immunity
and because their responses to IFNs are inhibited by their high
constitutive expression of USP18. Subcapsular sinus macrophages
rapidly become infected by viruses incoming from the lymph and
produce large amounts of IFNs. This altruistic suicide prevents
virus dissemination to other adjacent cell types and promotes the
induction of innate and adaptive anti-viral immunity (87).
HOW ARE IFNs PROMOTING ANTI-VIRAL IMMUNITY?
IFN direct anti-viral effector functions: induction of effector
molecules of cell-intrinsic anti-viral immunity
Upon instruction by IFNs, cells express a wide variety of viral
restriction factors, whose combined action blocks pathogen
invasion by interfering with the different stages of viral life
cycle (Figure 2A). This has been extensively reviewed recently
(88) and will only be described succinctly here. Virus fusion
with host cell membrane can be blocked by Cholesterol-25-
hydrolase (CH25H) that inhibits sterol biosynthesis. Some viruses
enter cells by escaping from endosomes/lysosomes, which can
be blocked by interferon inducible transmembrane (IFITM)
proteins. Virus uncoating can be blocked by tripartite motif
(TRIM) proteins, such as TRIM5α, which bind to HIV-1 cap-
sid thus promoting its degradation, and by Myxoma resistance
GTPases, MX1, and MX2, which efficiently trap viral structural
proteins at an early stage following virus entry into the cell.
MX1 inhibits a number of viruses, including influenza virus
through sequestration of its nucleocapsid. MX2 associates with
host cyclophilin A and HIV-1 capsid protein. Virion assem-
bly can be blocked at transcriptional, translational, and post-
translational levels. The adenosine deaminase acting on RNA
1 (ADAR1) and the apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like (APOBEC) deaminases induce viral
RNA destabilization and hypermutation (89, 90). The sterile
alpha motif and histidine-aspartic domain (HD) containing pro-
tein 1 (SAMHD1) blocks reverse transcription by hydrolyz-
ing dNTPs (91). ADAR1, APOBEC, and SAMHD1 functions
have been mainly studied in infections by HIV-1 and other
retroviruses. The 2′,5′-oligoadenylate synthase (OAS) proteins,
the IFN-induced proteins with tetratricopeptide repeats (IFIT),
FIGURE 2 | A simplified and schematic view of the modes of action
and specificities of ISG acting as direct anti-viral restriction factors. (A)
Different IFN-inducible restriction factors can block viral replication in
infected cells in a cell-intrinsic manner at different stages of the viral life
cycle. (B) Viral specificity (purple) might be inversely correlated to the
breadth of side effects on host cells (orange).
and PKR inhibit viral and host protein translation by using
complementary mechanisms (88). The major post-translation
modification induced by IFNs is the binding of the ubiquitin-
like modifier ISG15 to several viral and host proteins, a process
called ISGylation. Most of the known ISGylated proteins are tar-
geted for degradation, with few exceptions that are on the contrary
stabilized like IRF3 (88). Finally, the egress and budding of viri-
ons of many enveloped viruses can be inhibited by Tetherin or by
Viperin (88).
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Many anti-viral ISGs have been functionally characterized only
recently, largely thanks to large-scale screening approaches. They
display a variable degree of viral specificity (43, 92) that might
inversely relate to the extent of their side effects on host cells
(Figure 2B). Anti-viral effectors acting on a broad spectrum of
viruses often target key metabolic pathways that are also crucial
for host cell functions. This is the case for the control of cho-
lesterol metabolism by CH25H (93) or of protein translation by
PKR, OAS, or IFITs (88). Other anti-viral restriction factors such as
MX2 may specifically target one molecule of a very restricted set of
viruses with no apparent side effects on host cells. Some anti-viral
ISGs target specific functions critical for only a restricted array of
viruses and might similarly exert side effects only on a subset of
host cell types. For example, SAMHD1 inhibits retrovirus replica-
tion through dNTP depletion, which might more specifically affect
proliferating host cells. Hence, the infected host must balance
the intensity, breadth, and location of ISG induction to circum-
vent viral replication while preventing life-threatening damages
to vital cell types or tissues. One of the mechanisms contributing
to this balance is translational control of the expression of ISGs,
especially those with pro-apoptotic or anti-proliferative functions
(94). While many anti-viral ISGs are transcriptionally activated
in most IFN-stimulated cells, their translation can be specifically
blocked in uninfected cells by cellular microRNA. This inhibi-
tion is relieved upon cell infection through negative regulation of
the function of the RNA-induced silencing complex. Hence, IFN
stimulation of uninfected cells prepares them for rapid and strong
induction of cell-intrinsic anti-viral defenses upon viral infection
while avoiding their unnecessary exposure to the toxic effects of
certain ISGs.
Further knowledge on the functions and the dynamic regula-
tion of ISGs is essential to develop novel therapeutic strategies
against viral infections aiming at modulating IFN responses to
promote their protective anti-viral cell-intrinsic functions over
their deleterious toxic effects. A better understanding of the
immunoregulatory effects of IFNs will also help.
IFN orchestration of anti-viral responses of both innate and adaptive
immune cells
Type I interferon can modulate the functions of a broad spec-
trum of immune cells (Figure 3A). We will review this knowledge,
focusing on the functions of DCs, NK cells, T cells, and B cells,
since they are involved in the control of most viral infections. We
will discuss the hypothesis that DCs play a central role in IFN-I
orchestration of innate and adaptive immunity for the induction
of optimal anti-viral defenses (Figure 3).
During viral infections and cancer immunosurveillance, IFN-I
constitute one of the most important input signal acting on DCs
to promote their delivery of appropriate output signals to T cells,
B cells, and NK cells for protective immunity (Figure 3A). DCs
deliver three types of signals to activate and functionally polarize T
cells. Signal 1 is the triggering of the T cell receptor by viral peptide-
MHC complexes. Signal 2 is the triggering of activating T cell
co-stimulation receptors such as CD28 or CD27 by the CD80/86
and CD70 co-stimulation molecules expressed on DCs. Signal 3
corresponds to cytokines, which can promote T cell proliferation
and acquisition of specific effector functions. Under steady state
conditions, most DCs are in an immature state characterized by
low level expression of MHC-II (signal 1) and co-stimulation mol-
ecules (signal 2) and by the lack of production of T cell-activating
FIGURE 3 | DCs play a central role in IFN-I orchestration of innate and
adaptive immune responses. (A) IFN-I exert cell-intrinsic as well as indirect
effects on a variety of immune cell populations. DC responses to IFN-I play a
major role in promoting protective activation and functional polarization of
other innate and adaptive immune cells, not only during viral infections but
also in other physiopathological situations including cancer. (B) DC cell-
intrinsic responses to IFN-I endow them to deliver appropriate signals for T
cell priming and functional polarization. IFN-I can modulate all three types of
signals delivered by DC to T cells: MHC-I/antigenic peptide complexes ( ),
co-stimulation ( ), and cytokines ( ). This depends both on IFN-I-dependent
transcriptional induction in DC of some of the corresponding genes and on
IFN-I-dependent metabolic reprogramming of DC. (C) DC cell-intrinsic
responses to IFN-I endow them to deliver appropriate signals, in particular
IL-15 trans-presentation, for NK cell activation. See main text for further details.
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cytokines (signal 3). Upon activation, including early after viral
infections in vivo, DCs up-regulate their expression of signal 1
and activating signal 2 and secrete T cell-activating cytokines. This
process is called DC maturation. Gene expression profiling of DCs
stimulated by microbial stimuli identified a core set of genes up-
regulated in mature DCs irrespective of the stimulus they receive,
irrespective of the subset they belong to, and conserved across evo-
lution (95). Most of these genes are induced during DC maturation
in part through cell-intrinsic IFN-I signaling (95). Consistently,
cell-intrinsic IFNAR signaling in DCs is required in many cir-
cumstances for the induction of protective immunity, including
efficient CD8 T cell responses during viral infection or tumor
development (96–98), Th1 responses upon PolyI:C injection inde-
pendently of IL-12 or IFN-γ effects (99, 100), as well as follicular
helper T cell and humoral responses (101, 102). Mechanistically,
IFN-I promote DC immunogenicity for efficient T cell activation
through a variety of effects (Figure 3B). It drives DC up-regulation
of signal 2 in vivo during viral infections (103) and boosts their
capacity to cross-present antigens for increased delivery of signal
1 to CD8 T cells (96–98). It shapes their delivery of activating sig-
nal 3, in particular inducing IL-15 and promoting or inhibiting
IL-12 depending on experimental conditions (58, 104). Finally, it
is necessary to induce their metabolic shift from mitochondrial
oxidative phosphorylation to aerobic glycolysis, which fuels the
increased needs in energy and the expansion of the intracellu-
lar organelles required for the production and proper intracellular
routing of the signal 1 and 2 proteins (100, 105). Selective inactiva-
tion of IFNAR on cDCs compromises mouse resistance to MCMV
and MHV infections (103, 106). In contrast, IFNAR expression
is not required on NK cells for protection against MCMV and
on pDCs, T cells, and B cells for early control of MHV replica-
tion (103, 106). Although cell-intrinsic IFN-I signaling in NK cells
can promote their activation (107) (Figure 3A), IFN-I-induced
IL-15 trans-presentation by DCs plays a more prominent role for
this function in many conditions including in vivo during MCMV
infection (103, 108) (Figure 3C).
Cell-intrinsic IFN-I signaling in CD4 T cells (109), CD8 T cells
(110, 111), and B cells (112) can also contribute to their efficient
activation and functional polarization (Figure 3). This depends
on experimental settings. CD8 T cell-intrinsic IFN-I responses
are crucial for mounting efficient cytotoxic CD8 T cell responses
against LCMV but are less critical against Vaccinia virus and vesic-
ular stomatitis virus (110, 113, 114). Mechanistically, cell-intrinsic
IFN-I signaling in CD8 T cells can promote their survival during
their antigen-induced proliferation (110). Cell-intrinsic signaling
in DCs and CD8 T cells may act in a synergistic manner. Indeed,
conditional inactivation of IFN-I responsiveness was required to
occur simultaneously in both of these two cell types to dramati-
cally affect CD8 T cell expansion upon vaccination with a modified
Ankara vaccinia virus (115).
In summary, IFN-I generally play a crucial, beneficial, role in
immune defenses against viral infections, both through the induc-
tion of cell-intrinsic anti-viral defenses and through the orchestra-
tion of innate and adaptive immunity. However, if these responses
are not properly regulated, they can contribute to diseases as we
will now discuss.
DIFFERENT, AND SOMETIMES OPPOSITE, PROCESSES
UNDERLIE DELETERIOUS IFN-I RESPONSES DEPENDING ON
THE PHYSIOPATHOLOGICAL CONTEXTS
DELETERIOUS EFFECTS RESULTING FROM THE INDUCTION OF
UNBRIDLED INFLAMMATORY RESPONSES CAUSING SEVERE TISSUE
DAMAGE, AS EXEMPLIFIED IN AUTOIMMUNE DISEASES
A frequent side effect of IFN-I treatment against cancer or chronic
viral infections is the induction of autoimmune reactions. Consis-
tently, ISG expression is a hallmark of many spontaneous systemic
or tissue-specific autoimmune diseases, including systemic lupus
erythematosous (SLE), Sjogren’s syndrome, psoriasis, and other
skin disorders (11). The dysregulation of IFN-I responses observed
in patients with these autoimmune diseases likely results from
both genetic and environmental factors. Genome-wide associa-
tion studies show that polymorphisms in genes involved in IFN-I
responses strongly correlate with increased susceptibility to many
autoimmune diseases (11). Diverse environmental factors can
also contribute to the onset of autoimmune diseases. Microbial
infections often precede first clinical manifestations of autoim-
mune diseases. Whether infections (116) and/or alterations in the
commensal microbiota of the affected barrier tissues (117, 118)
are the cause or rather the consequence of autoimmunity is still
matter of debate. Infection- or dysbiosis-induced tissue damages
and unbridled IFN-I responses can contribute to initiate autoim-
mune reactions. Gender is another prominent factor affecting
susceptibility to autoimmune diseases. Women are more prone
to autoimmunity, which may result from endocrine regulation of
IFN-I responses. pDC IFN-I production is enhanced in human
and mouse females, due at least in part to cell-intrinsic enhance-
ment of TLR7/9 responses by the female hormone estradiol (119).
In autoimmune diseases, different mechanisms could operate to
initiate the dysregulation of immune responses leading to a vicious
circle of reciprocal activation between innate IFN-I responses and
adaptive self-reactive lymphocyte responses (Figure 4). Adaptive
immune cells are educated to spare “self.” This occurs through
negative selection of potentially autoimmune B and T cells during
their development in the bone marrow or thymus, respectively,
a process called central tolerance. Self-reactive B or T cells that
have escaped this pruning can be either deleted or functionally
inactivated once they have egressed in secondary lymphoid organs
or non-lymphoid tissues, a process called peripheral tolerance. In
some individuals, polymorphisms in genes involved in the pro-
motion of central or peripheral tolerance lead to a higher number,
diversity, and/or responsiveness of self-reactive lymphocytes in
the periphery, in particular of B cells secreting anti-DNA or anti-
RNP antibodies (120, 121). Mammalian DNA or RNA are poor
inducers of pDC IFN-I induction under normal conditions. How-
ever, pre-existing anti-DNA or anti-RNP autoantibodies can break
this innate tolerance of pDC. Indeed, antibodies binding to self
nucleic acids can protect them from degradation and compact
them into nanoparticles that are very effective for the induction
of IFN-I in pDC (Figure 4). DNA-containing immune com-
plexes (ICs) are frequently found in the serum of SLE patients
(SLE-ICs) and can activate pDC IFN-I production (122). In turn,
pDC IFN-I activate cDCs, monocytes (123), and B cells, lead-
ing to a vicious circle of reciprocal activation between DCs and
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FIGURE 4 | A simplified model of the deleterious role of IFN-I in several
autoimmune diseases. When exposed to different kinds of injuries
(microbial infection, commensal microbiota dysbiosis, chemical or physical
insults), healthy tissues can undergo cell damage and death. These events
induce the release of apoptotic bodies encompassing self RNA or DNA.
Neutrophil recruitment and activation in inflamed tissues can also constitute
a potent source of self nucleic acids, through the release of neutrophil
extracellular traps (NET). Self RNA or DNA can associate with cationic
peptides (e.g., LL37) as shown in psoriatic patients or with inflammatory
molecules (e.g., high mobility group box 1, HMGB1) to generate
nanoparticles that are extremely efficient for IFN-I production by pDC and
eventually other cell types. pDC can also be efficiently activated for IFN-I
production by immune complexes (ICs) generated by the association
between self nucleic acids and auto-antibodies as frequently found in the
serum of systemic lupus erythematosus patients. IFN-I promote the
differentiation and/or the maturation of antigen-presenting cells, in particular
different subsets of DC. Activated DC can then present self-antigens for
activation of auto-reactive T CD4+ cells, including follicular helper
lymphocytes, which in turn activate auto-reactive B cells for auto-antibody
secretion, leading to a vicious circle of reciprocal activation between innate
and auto-reactive adaptive immune cells. iDC, immature DC; mDC, mature
DC; Mo-DC, monocyte-derived DC. See main text for further details.
self-reactive lymphocytes and to the exacerbation of autoimmune
responses (Figure 4). Certain infections or dysbiosis of the com-
mensal microbiota of the affected barrier tissues could promote
chronic production of host amphiphatic peptides able to combine
with eukaryotic DNA or RNA, likely released from dying cells,
thus forming pDC-activating nanoparticles. Indeed, in psoriatic
skin, both a high expression of LL37 and a massive infiltration of
pDCs is observed (124) (Figure 4). Hence, to treat many autoim-
mune diseases, novel therapeutic strategies could be designed to
target dysregulated pDC IFN-I production or B cell activation by
IFN-I.
DELETERIOUS RESPONSES RESULTING FROM INAPPROPRIATE
FUNCTIONAL POLARIZATION OF IMMUNE RESPONSES, AS
EXEMPLIFIED IN FAILURE TO CONTROL SECONDARY BACTERIAL OR
FUNGAL INFECTIONS
One of the most common complications of primary infections
by many respiratory viruses, in particular influenza virus, is a life-
threatening pneumonia due to secondary pulmonary infections by
bacteria, such as Streptococcus pneumoniae, Staphylococcus aureus,
or Haemophilus influenza (125, 126). These pathologies affect
especially infants, elderly, and immunocompromised patients.
Retrospective studies indicate that secondary bacterial pneumonia
was highly recurrent in lung tissues isolated from patients who died
during last century influenza pandemics, independently of antibi-
otic availability (127, 128). Influenza virus induces high IFN-I
responses in human beings and mice. In both hosts, secondary bac-
terial infections are lethal only when they occur in a limited time
window following primary viral infection (3–7 days), around the
peak of IFN-I responses, before complete virus clearance. Mouse
models of viral/bacterial coinfections are being used to dissect
disease mechanisms (129). IFNAR1-deficient mice appear more
resistant to secondary pulmonary bacterial infections, showing
that IFN-I responsiveness contributes to disease (130). Similarly,
after lymphochoriomeningitis virus (LCMV) infection, wild-type
but not IFNAR1-deficient mice are more susceptible to LPS-
induced septic shock (131). Several mechanisms may contribute
to the detrimental role of IFN-I in secondary bacterial infections
(Figure 5). Early during viral infection, IFN-I decrease the host
ability to control bacterial replication, by dominantly polarizing
immune responses toward anti-viral functions, simultaneously
inhibiting the development of the types of immune responses
required for protection against most bacterial infections. IFN-I can
inhibit the production of chemokines required for the recruitment
to the respiratory tract of antibacterial effector innate immune
cells, in particular neutrophils or monocytes/macrophages (132,
133) (Figure 5). Depending on the experimental models used,
IFN-I can on the contrary induce a CCR2-dependant recruit-
ment of classical monocytes (134). In infected tissue, IFN-I might
skew the functional polarization of resident or infiltrating mono-
cytic cells toward immunosuppression, because it does limit their
antibacterial functions by inhibiting their IL-1 production (135–
137) while it might promote their production of IL-10 and nitric
oxygen intermediates. The exact nature of infiltrating mono-
cytic cells is not clear and could correspond to activated classical
monocytes, MoDCs, monocyte-derived macrophages, or myeloid-
derived suppressor cells (MDSCs). The boundaries between these
putatively different cell types are currently ill-defined (138). These
cells could fuel local replication of monocyte/macrophage-tropic
bacteria (134), be immunosuppressive (139) or contribute to
local immunopathology (140). The role of IFN-I on mono-
cytes/macrophages is complex and will require further investiga-
tions to determine when it is protective versus deleterious and
what the underlying mechanisms are. Depending on the con-
text, IFN-I can either promote or inhibit the induction of Th1
cytokines such as IL-12 and IFN-γ, and myeloid cell responses to
IFN-γ (10, 141-143). IFN-I can also polarize CD4 T cell responses
toward Th1 at the expense of Th17, while the Th17-type cytokines
IL-17A and IL-22 are required for host defense against pulmonary
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FIGURE 5 | A simplified model of the deleterious role of IFN-I in
secondary pulmonary bacterial infections or in fungal infections and of
their protective role in multiple sclerosis (MS). IFN-I-dependent signals
can block CXCL1 and CXCL2 production, thus inhibiting the recruitment and
activation of neutrophils in inflamed tissues, hampering their protective
functions against secondary pulmonary bacterial infections or fungal
infections. IFN-I-dependent signals can enhance CCL2 production,
promoting the recruitment in inflamed tissues of CCR2+ monocytes that
can potentially differentiate into TipDC or into MDSC. This can contribute to
disease either through enforcing T cell activation leading to
immunopathology or on the contrary through suppressing anti-microbial
immune defenses. IFN-I can either inhibit or promote Th1 responses, which
in the latter case occurs at the expense of Th17 responses thus
compromising the production of IL-17 and IL-22, which are respectively
required for control of microbial replication and for tissue healing.
IFN-I-induced IL-10 and IL-27 can directly inhibit Th17. In MS, inhibition of
Th17 functions may contribute to the protective effects of IFN-β therapy.
MPO, myeloperoxidase; TNF, tumor necrosis factor alpha; NO, nitric oxide.
See main text for other abbreviations and further details.
bacteria by inducing the production of anti-microbial peptides
and of tissue repair molecules (Figure 5) (141–143). IFN-I may
not only affect host resistance to bacterial infection, but also host
tolerance, i.e., the ability of the host to tolerate a given burden
of pathogen without undergoing excessive tissue damages (143,
144). Hence, to counter IFN-I deleterious effects during secondary
bacterial infections, it will be important to better delineate the
respective contribution of lung tissue tolerance modulation and
of immune-mediated resistance weakening.
Another well documented example of deleterious effects of
IFN-I due to their inappropriate functional polarization of
immune responses is the enhanced susceptibility to fungal infec-
tions of patients with genetically determined hyperactive IFN-I
responses, as exemplified in the hereditary disease Chronic Muco-
cutaneous Candidiadis (CMC) (Figure 5) (145). Patients with
CMC have a significant deficit in Th17 CD4 T cells, at least in
part as a consequence of altered responsiveness to IL-6 or IL-21.
Several STAT1 mutations were identified in patients with auto-
somal dominant CMC. Gain-of-function STAT1 mutations were
found to hard wire CD4 T cell responses to cytokines toward
STAT1 signaling, compromising their STAT3-dependent ability to
produce IL-17 upon IL-6 or IL-21 stimulation. This was associated
to induction of a global IFN-I transcriptomic signature in blood
(145). Deleterious IFN-I effects on immunity to Candida might
not only occur in CMC patients but also in other types of indi-
viduals upon secondary fungal infections occurring shortly after
a primary viral infection, likewise to the situation discussed above
for secondary bacterial infections. Indeed, PolyIC induced IFN-I
abrogate innate immunity to systemic candidiasis in mice (146),
and IFNAR-deficient mice can be more resistant to Candida infec-
tion under certain experimental settings (147). However, the role
of IFN-I in the modulation of the ability of immunocompetent
hosts to control fungal infection is disputed (148, 149).
The inhibition of Th17 responses by IFN-I could be protec-
tive in at least one important human pathology, MS (Figure 5).
MS represents a striking exception to the previously discussed
detrimental role of IFN-I in autoimmune diseases. Indeed, a large
proportion of MS patients have low serum IFN-I activity and low
ISG levels. These MS patients present a significant reduction of
MS relapse upon IFN-β administration (150). The underlying
mechanisms are not yet completely unraveled. However, in the
experimental autoimmune encephalitis mouse model of MS, Th17
responses bear a major contribution to nervous system damages
and are inhibited by the IL-10 and IL-27 induced upon IFN-I
administration (151).
In summary, IFN-I responses can be deleterious in autoim-
munity by promoting a vicious circle of reciprocal activation
between innate immune cells and auto-reactive CD4 T or B lym-
phocytes. IFN-I responses can also be deleterious upon secondary
bacterial or fungal infections in the lung or the kidneys occur-
ring shortly after a primary viral infection, by compromising the
recruitment of anti-microbial innate effector cells and/or by pre-
venting the proper functional polarization of immune responses.
We will now discuss how IFN-I responses can also compromise
host immune defenses against certain viruses and promote chronic
infections.
DELETERIOUS RESPONSES RESULTING FROM THE INDUCTION OF
IMMUNOSUPPRESSION, AS EXEMPLIFIED IN CHRONIC LCMV
INFECTION
Different LCMV strains such as Armstrong and clone-13 (Cl13),
respectively, lead to acute versus chronic infections in mice. A
hallmark of chronic LCMV infection is the loss of the prolifer-
ative potential and effector functions of anti-viral CD8 T cells, a
process called exhaustion. Exhausted CD8 T cells are characterized
by a high expression of the inhibitory receptors PD-1, CTLA4, and
LAG-3 (152). In vivo blockade of these inhibitory receptors can
reverse T cell exhaustion and allow resolution of the chronic infec-
tion (152). IFN-I and ISGs are induced early after infection with all
strains of LCMV, albeit to lower levels with those leading to chronic
infection. This early IFN-I production is critical to limit viral repli-
cation (3). In models of acute infection, IFN-I responses rapidly
return to normal, undetectable, levels, before viral replication is
completely controlled. In contrast, ISG induction is maintained
in chronic infection, including the expression of PD-1 ligands on
APCs and of the immunosuppressive IL-10 cytokine, consistent
with a prolonged expression of IFN-I albeit at low levels (13, 14).
In vivo neutralization of IFN-I by antibody administration pro-
moted resolution of chronic LCMV Cl13 infection, allowing the
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restoration of functional anti-viral CD8 T cell responses at least
in part through CD4 T cell- and IFN-γ-dependent mechanisms
(13, 14). During persistent LCMV Cl13 infection, chronic low
level IFN-I production polarizes CD4 T cell responses toward T
follicular helper (Tfh) rather than Th1 functions. Thus, chronic
IFN-I responses promote enhanced anti-viral B cell responses but
facilitate CD8 T cell exhaustion due to deficient CD4 T cell help,
therefore contributing to host failure to prevent chronic infec-
tion (153). Strikingly, establishment of chronic infection by LCMV
Cl13 could also be prevented by early administration of two shots
of a high dose of exogenous IFN-I, at days 2 and 5 post-LCMV
inoculation. This treatment allowed viral clearance by rescuing
anti-viral CD8 T cell from exhaustion (154). Altogether, these
studies show that the timing and duration of IFN-I production
during viral infections is critical in determining how this response
will impact the balance between the virus and the host. An early
and robust but transient production of IFN-I promotes strong
induction of cell-intrinsic viral restriction mechanisms as well as
adequate polarization of adaptive anti-viral immune responses,
which combined effects lead to viral clearance. In contrast, if the
production of IFN-I is too low and/or too late, both viral repli-
cation and low IFN-I responses become chronic, their combined
action leading to induction of immunosuppressive effects and to
inadequate functional polarization of CD4 T cells. This results
in CD8 T cell exhaustion and maintenance of chronic infection.
Chronic viral replication and CD8 T cell exhaustion is also a hall-
mark of HIV-1 infection. We will now discuss the complex and
disputed role of IFN-I in this disease.
THE COMPLEX AND DISPUTED ROLE OF IFN-I IN HIV-1 INFECTION
Both in HIV-1 infection and in its most relevant animal model,
infection of non-human primates with simian immunodeficiency
virus (SIV), disease progression after the acute phase of the infec-
tion is associated with high and chronic expression of ISGs while
IFN-I production is inconsistently detected (155–157). In con-
trast, the individuals that do not progress toward disease despite
persistent high viral loads show much lower immune activation,
in particular low ISG expression, after the acute phase of the infec-
tion (158–161). Hence, chronic low levels of IFN-I are associated to
disease progression independently of the level of viral replication.
Therefore, an outstanding question still open for a better under-
standing of the physiopathology of HIV-1 infection is whether
chronic IFN-I responses are merely a marker of progression, or
whether they are implicated in driving disease development. In
addition to mechanisms similar to those uncovered in the mouse
model of chronic LCMV infection, during HIV-1 infection other
effects of IFN-I could promote a vicious circle of reciprocal activa-
tion between chronic viral replication and sustained, deleterious
immune responses (Figure 6). Very early after HIV-1 infection, in
most individuals, IFN-I production might be too weak or too late
to induce a combination of cell-intrinsic defense mechanisms and
of immune responses efficient enough to prevent later establish-
ment of chronic infection. On the contrary, as demonstrated in
the case of the mouse model of LCMV infection, IFN-I responses
could favor CD8 T cell exhaustion, either by direct cell-intrinsic
effects on CD8 T cells (Figure 6, ) or by contributing to deprive
them from CD4 T cell help (Figure 6, ). Several effects of IFN-I
might compromise anti-HIV-1 Th1 responses or more generally
contribute to the global depletion of CD4 T cells. These mecha-
nisms include functional polarization of anti-HIV-1 CD4 T cells
toward Tfh rather than Th1 responses, CXCL10 production lead-
ing to enhance recruitment of memory CD4 T cells to the sites
of viral replication where they fuel chronic viral replication with
new HIV-1 target cells (Figure 6, to ), direct pro-apoptotic
and anti-proliferative effects on CD4 T cells (Figure 6, ), as
well as TRAIL induction on pDCs licensing them for killing
CD4 T cells irrespective of their infection (Figure 6, ) (162,
163). Altogether, these mechanisms entertain chronic viral repli-
cation and continuous depletion of CD4 T cells, leading to the
dramatically enhanced susceptibility to opportunistic infections
(Figure 6, ) characteristic of the acquired immunodeficiency
syndrome (AIDS) (Figure 6, ). Other lines of evidences have
been reported to support a deleterious role of pDC activation
during HIV-1 infection. Women undergo faster HIV-1 disease
progression than men with similar viral loads, which may result in
part from the highest IFN-I production of women’s pDCs includ-
ing in response to HIV-1 stimulation (164). pDC recruitment and
activation in the vaginal mucosa of female macaques early after
local SIV inoculation contribute to attract and activate CD4 T
cells, which can then be infected and promote virus dissemina-
tion from its portal of entry (165). However, in vivo blockade of
pDC IFN-α production by administration of TLR7/9-antagonistic
oligonucleotides early after SIV infection of macaques did not
decrease T lymphocyte activation, which suggests that additional
sources of IFN-I likely contribute to the immune dysfunction
observed in SIV/HIV-1 infections. Targeting dysregulated IFN-I
responses during HIV-1 infection might represent an interest-
ing adjuvant therapeutic strategy to highly active antiretroviral
treatments. Administration of IFN-I in the non-pathogenic SIV
infection model of sooty mangabeys was not sufficient to switch
it into a pathogenic model. No CD4 T cell depletion ensued, no
hyperactivation of immune responses were observed. Viral loads
were even significantly decreased. However, this could be con-
sistent with the positive impact of early and high dose IFN-I
administration in chronic LCMV infection (154). Indeed, during
the review process of this manuscript, it was reported that, early
during primary SIV infection in the pathogenic rhesus macaque
model, a high dose injection of IFN-I was protective while neutral-
ization of endogenous IFN-I was deleterious. In contrast, in the
same animal model, prolonged IFN-I administration accelerated
disease development in the chronic stage of the infection (166). In
mice with a humanized immune system, pDC depletion strongly
decreased ISG induction and enhanced viral replication both in
the acute and chronic phases of HIV-1 infection. However, pDC
depletion during chronic infection decreased infection-induced T
cell apoptosis and increased T cell numbers in lymphoid organs
(167). These results further emphasize the dual role of IFN-I and
pDCs in the physiopathology of HIV-1 infection. A strong and
transient production of IFN-I early after infection benefits the host
by lowering the set-point of viral replication during chronic infec-
tion. Sustained production of low levels of IFN-I during chronic
infection contributes to immune dysregulation and CD4 T cell
depletion. Further studies will be necessary to examine whether
complementing standard-of-use antiretroviral drugs with pDC
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FIGURE 6 | Potential mechanisms through which chronic, low level IFN-I
production might promote disease progression in HIV-1 infection. High
and sustained expression of ISG in blood and lymphoid organs is a hallmark of
progressive infection with immunodeficiency viruses both in human beings
and in non-human primates, irrespective of the levels of viral replication.
Several mechanisms summarized here have been proposed to explain how
chronic, low level IFN-I production might promote disease progression in
HIV-1 infection. These mechanisms include direct ( ) and indirect ( )
promotion of the exhaustion of anti-viral CD8 T cell responses, as well as
direct ( ) and indirect ( -to- , and ) promotion of CD4 T cell depletion
with a proposed central role of pDC in this deleterious process. Altogether,
these mechanisms may sustain a vicious circle of reciprocal activation
between chronic viral replication and deleterious immune responses, driving
the progressive depletion of all CD4 T cells ultimately causing the enhanced
susceptibility to opportunistic infections characteristic of the acquired
immunodeficiency syndrome (AIDS). See main text for further details.
depletion, IFN-I neutralization, or selective inhibition of T cell
responses to IFN-I could yield additional benefits to chemotherapy
in non-human primates during chronic SIV infection.
IFN-I administration has been used for many years to treat
another human chronic viral disease, HCV infection. Roughly,
half of the patients do not show sustained virological responses
(SVR). The treatment causes severe side effects in many individ-
uals. New chemotherapeutic drugs very potent at blocking HCV
replication in vivo have recently become available. Hence, whether
IFN-I administration still constitutes a viable treatment against
chronic HCV infection is being questioned (168, 169). We will
now discuss this issue.
IFN-I TREATMENT OF CHRONIC HCV INFECTION: BALANCING BENEFITS
FOR VIRUS CONTROL WITH SIDE EFFECTS STRONGLY AFFECTING
PATIENT’S QUALITY OF LIFE
Chronic HCV infection is the main cause of liver cirrhosis and
hepatocellular carcinoma. There is currently no vaccine against
HCV. The most common therapy for chronic HCV patients is
the administration of recombinant pegylated IFN-α (Peg-IFN-α)
combined with the anti-viral drug ribavirin. However, because
of IFNAR pleiotropic expression, IFN-α administration induces
severe side effects including flu-like syndrome, fever, fatigue,
myalgia, and nervous depression (Figure 7A) (170). Moreover,
only about half of treated patients harbor SVR (171). Prior-to-
treatment high hepatic ISG expression is a negative predictor of
SVR upon Peg-IFN-α therapy. High ISG expression in untreated
patients likely results from chronic but low IFN-I production trig-
gered by persistent HCV replication. Indeed, hepatocytes from
non-responder patients were found to be infected at a greater fre-
quency and to exhibit dampened antiviral and cell death responses
(172). What the cellular sources of IFN-I production are and why
they persist only in non-responder patients still remain to be estab-
lished. In chronic HCV infection, cytotoxic effector lymphocytes
may contribute to the development of hepatocarcinoma by causing
low level but sustained hepatocyte death and renewal. In contrast,
local production of IFN-γ in the liver by NK and T lymphocytes
could promote resistance to disease through non-cytolytic control
of viral replication. As discussed previously for LCMV and HIV-
1, low chronic production of endogenous IFN-I in HCV patients
could compromise both innate and adaptive anti-viral immune
responses. Chronic exposure to IFN-I could dampen the ability of
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FIGURE 7 | A novel hypothetical model attempting to explain the
respective roles of IFN-I and IFN-III in HCV infection. (A) Classification of
patients suffering from chronic HCV infection and treated with PEG-IFN-α in
non-responders and responders, and identification of IFNL3 (IL28B) gene
polymorphisms as the best predictors for treatment response. The
side-effects induced by PEG-IFN-α treatment are also listed since they can
severely affect the patient’s quality of life and lead to treatment failure due
lack of compliance or suicide. Hence, new approaches are needed to promote
beneficial over deleterious effects of IFN-I administration in chronic HCV
infection. (B) Proposal of a new hypothesis explaining the relationships
between endogenous ISG levels in patients prior to treatment, IFNL3 gene
polymorphism, endogenous expression of IFN-I, IFN-λ, and IFNλR1, and
responsiveness to IFN-I administration. Efficient control of HCV infection may
depend on hepatocyte response to IFN-λ rather than IFN-α. Upon HCV
infection, the virus induces the expression of host miRNA able to bind the 3′
UTR of IFNL3 mRNA to promote their degradation. The favorable IFNL3 allele
associated with responsiveness to PEG-IFN-α treatment may allow
endogenous expression of sufficient levels of IFNL3 for efficient induction of
cell-intrinsic anti-viral defenses in hepatocytes. This process is, however,
hampered by the limited expression of the receptor for this cytokine (IFNλR1)
in these patients. PEG-IFN-α treatment might promote resolution of the
infection by inducing IFNλR1 in these patients, potentiating their response to
their endogenous production of IFNL3. In the patients that do not respond to
PEG-IFN-α treatment, endogenous levels of IFNL3 are insufficient for efficient
induction of cell-intrinsic anti-viral defenses in hepatocytes, due to the
degradation of the corresponding mRNA in infected hepatocytes. In these
patient’s hepatocytes, however, IFNλR1 is already expressed to high levels
prior to treatment due to their high endogenous IFN-I responses.
Administration of exogenous IFN-λ might cure these patients. See main text
for further details.
NK and CD8 T cells to produce IFN-γ (173, 174) and promote
CD8 T cell exhaustion (175). It could also induce an antagonist
form of CXCL10, a chemokine required for recruitment to the
liver of anti-viral NK and CD8 T cell effectors (176). It may also
polarize monocytes toward immunosuppressive functions (177).
Therefore, better understanding IFN-I effects in HCV infection is
critical to improve care of both responders and non-responder
patients to Peg-IFN-α. For responder patients, the issue is to
modify the treatment to favor beneficial antiviral and immunoac-
tivating effects over side effects strongly affecting patient’s quality
of life (Figure 7A). This might be achieved by specific delivery of
IFN-I to targeted cell types as discussed later. For non-responder
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patients, the issue is to understand the mechanisms underlying
treatment failure to determine whether alternative therapies could
be designed (Figure 7A).
Genome-wide association studies identified various single
nucleotide polymorphisms (SNP) in the gene encoding IL-
28B/IFN-λ3, one of the IFN-III, as well in its 5′ and 3′ non-coding
regions (178–181). One SNP, called rs12979860, is located 3 kb
upstream of the IFNL3 gene. Patients harboring the CC genotype
have a favorable prognosis to IFN-I treatment. Patients with the
TT genotype are at high risk of treatment failure (178, 179). In
Europeans, the favorable CC genotype is the major, most com-
mon, IFNL3 allele. The unfavorable TT SNP is the minor allele.
The frequency of these alleles is reversed in Africans. The favorable
allele allows escape of IFNL3 mRNA from degradation by cellular
microRNA induced upon HCV infection (181).
Until recently, IFNL3 genotypes and hepatic ISG expression
were considered as independent predictors of response to Peg-
IFN-α treatment in HCV patients (171). Here, we propose a
potential explanation, which integrates both factors in a rela-
tively simple model (Figure 7B). Our main hypothesis is that
efficient control of HCV infection depends on hepatocyte response
to IFN-λ rather than IFN-α. This is supported by reports that
IFN-λ induces a stronger and more sustained ISG expression in
hepatocyte cell lines in vitro (182), and that PolyI:C-induced con-
trol of HCV replication in humanized liver in chimeric mice is
correlated to the induction of IFN-λbut not IFN-I in human hepa-
tocytes (183). Responder patients harboring the favorable IFNL3
allele preventing the degradation of the corresponding RNA in
infected cells might express significant levels of endogenous IFN-
λ3, although this is disputed. However, they express only low levels
of IFN-λR1, which limits IFNλ3 efficiency (Figure 7B) (184).
How these patients benefit from Peg-IFN-α treatment could be
that it induces IFN-λR1 expression on hepatocytes thus boosting
endogenous IFN-λ3 effects (184). In contrast, high ISG-expressing
non-responder patients harboring the unfavorable IFNL3 allele
might not express enough IFN-λ3 for virus control. However,
they do express IFN-λR1 as a result of their endogenous pro-
duction of IFN-I. Hence, Peg-IFN-α might be ineffective in these
patients because they already express IFN-λR1 but fail to pro-
duce endogenous IFN-λ3 due to the degradation of its mRNA
in infected hepatocytes (Figure 7B). These patients may be good
candidates for Peg-IFN-λ therapy, currently undergoing clinical
development. Since the expression of IFN-λR1 is mainly restricted
to epithelial cells, melanocytes, and hepatocytes, some of the side
effects related to IFN-I treatment might be strongly attenuated in
Peg-IFN-λ therapy. However, as IFN-I are key to induce anti-viral
immune responses, it will be critical to determine whether, beside
viral clearance, Peg-IFN-λ therapy can also induce long-term
immune protection against HCV.
CELLULAR AND MOLECULAR MECHANISMS DETERMINING
THE BENEFICIAL VERSUS DELETERIOUS OUTCOME OF IFN-I
EFFECTS
EXISTENCE OF DIFFERENT PATHWAYS DOWNSTREAM OF IFNAR
SIGNALING
IFN-I transduce intracellular signals through a single receptor,
IFNAR, but via a multitude of downstream signaling pathways.
The Janus activated kinase (JAK)/STAT pathway was the first
to be identified (185). IFNAR is composed of two distinct sub-
units, IFNAR1 and IFNAR2, which are constitutively associated
with members of the JAK family, tyrosine kinase 2 (TYK2) and
JAK1, respectively (186). The binding of IFN-I to their recep-
tor leads to the phosphorylation of JAK1 and TYK2, which in
turn induce the phosphorylation and activation of the STAT
proteins (186).
Different STAT complexes can form upon triggering of IFNAR
(Figure 8). A transcriptional complex that forms in most condi-
tions of IFN-I stimulation and induces the expression of many
molecules of cell-intrinsic anti-viral immunity is interferon-
stimulated gene factor 3 (ISGF3), a heterotrimer composed of
pSTAT1, pSTAT2, and IRF9 (187) (Figure 8). Following its translo-
cation into the nucleus, ISGF3 binds to ISRE regulatory sequences
in target genes. Many molecules playing a key role in the func-
tion of innate or adaptive immune leukocytes are also induced by
ISGF3, including CD80, CD86, or IL-15 in DC, and Granzyme B in
NK cells. ISGF3 is generally composed of STAT1 phosphorylated
on Tyr701 and Ser727 and of STAT2 phosphorylated on Tyr689.
However, alternative ISGF3 complexes have been described in var-
ious contexts which could participate to the diversity of IFN-I
effects (188).
The pSTAT1 homodimer also plays a prominent role in
cell-intrinsic IFN-I-dependent gene induction. It binds IFNγ-
activated sequences (GAS) and controls the expression of many
pro-inflammatory molecules (187). pSTAT1 homodimers can
form upon stimulation with either IFN-I or IFN-γ. Many GAS-
regulated genes can be induced by either cytokines.
Depending on cell types, JAK signaling downstream of IFNAR
can lead to the activation of virtually all STAT proteins and to
their combinatorial association into a variety of complexes with
different affinities for specific GAS elements (189–191) (Figure 8).
This diversity contributes to IFN-I induction of different tran-
scriptional programs in distinct cell types (39). STAT complex
formation depends in part on the relative abundance of STAT
molecules in the cell (192). While STAT1, STAT2, STAT3, and
STAT5 can be activated in most cell populations, STAT4 and
STAT6 are mainly activated in lymphocytes (193). For exam-
ple, quiescent NK cells express more STAT4 than STAT1, leading
to constitutive association of IFNAR to STAT4 in these cells.
Hence, quiescent NK cells mount pSTAT4 homodimer-dependent
responses to IFN-I stimulation, including IFN-γ production and
T-bet-driven proliferation (Figure 8) (194, 195). Changes in STAT
levels can also occur upon the differentiation/activation of a given
cell type and lead to a shift in its functional response to the
cytokines (196). Upon activation, NK cells decrease their expres-
sion of STAT4 and increase that of STAT1, shifting their IFN-I
response from STAT4-dependent in a quiescent state to STAT1-
dependent in pre-activated cells. This translates into opposite
IFN-I effects on IFN-γ production and proliferation for quiescent
versus pre-activated NK cells (194). However, this outcome can
be modulated by simultaneous exposure to other cytokines such
as IL-15 or IL-12/18. A reverse STAT1-to-STAT4 shift occurs in
DC during their maturation, shifting their functional responses
from inhibition to activation of IL-12 production in response
to combined stimulations with IFN-I and CD40L (197). This
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FIGURE 8 | Schematic representation of the ISGF3 and alternative
JAK/STAT signaling pathways induced by IFN-I. The receptor for
IFN-I, IFNAR, is composed of two chains, IFNAR1 and IFNAR2, which
are respectively associated with the JAK family kinases TYK2 and JAK1.
IFN-I binding to IFNAR triggers the phosphorylation of TYK2 and JAK1,
which in turn phosphorylate a variety of STAT proteins. Activated STATs
are able to form complexes, as homo- or hetero-dimers. The heterodimer
STAT1-STAT2 binds to a third partner, IFN-regulatory factor 9 (IRF9), in
order to form the ISGF3 complex. This complex translocates into the
nucleus and binds to specific regulatory sequences, IFN-stimulated
response elements (ISRE), to activate the expression of many
interferon-stimulated genes (ISGs). In particular, ISGF3 induces most, if
not all, of the ISGs encoding effector molecules of cell-intrinsic anti-viral
defenses such as OAS or MX1. Alternative JAK/STAT pathways include
the formation of STAT1 or STAT4 homodimers, which may drive different
functional responses to IFN-I. STAT1 homodimers bind to IFNγ-activated
sequences (GAS) in the promoter of certain ISGs, which may promote
inflammatory, anti-proliferative, and pro-apoptotic responses. STAT4
homodimers also bind to GAS but promote IFN-γ production and
pro-proliferative responses.
enables mature DC to efficiently activate CD8 T cells. Other yet
unknown mechanisms control the formation of different STAT
complexes in distinct cell types. The nature and dynamics of the
signaling pathways triggered by IFN-α or -β were evaluated in
bulk cultures of human blood leukocytes using flow cytometry
(191) or high throughput mass cytometry (190). A diversity of
phosphorylation patterns of STAT1/3/5 was observed upon IFN-I
stimulation. IFN-α activation induced phosphorylation of STAT1,
STAT3, and STAT5 in most cell types, peaking at 15 min (190).
IFN-β-induced STAT1 phosphorylation was found to be poor in
B cells as compared to monocytes and T cells (191). However,
the underlying mechanism remains to be identified since B cells
did not express lower amount of IFNAR2 or STAT1 or enhanced
levels of the inhibitory SOCS1 molecule. The high STAT1 acti-
vation in monocytes led to their induction of IFN-I-dependent
pro-apoptotic genes while this was not the case in B cells. These
results strikingly differ from those obtained in the other study
upon IFN-α stimulation, where STAT1 phosphorylation was on
the contrary lower in CD14+ monocytes and was prolonged in
B cells and NK cells (190). The differences between these two
studies might have resulted from the use of different subsets and
doses of IFN-I. In any case, both studies consistently reported
that CD4 T cells showed the highest activation of STAT5. All
CD4 T cells but not all CD8 T cells activated STAT5 and for
a longer time (190). IFN-β activation of STAT3 was delayed
in CD4 T cells and B cells as compared to CD8 T cells and
monocytes (191). Different STAT complexes may lead to distinct
transcriptional programs linked to different biological functions
(Figure 8). More systematic studies are needed to understand this
complexity. Besides changing STAT levels between cell types or
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activation states, the processes controlling differential formation
of STAT complexes downstream of IFNAR triggering remain to be
identified.
In addition to JAK/STAT signaling, other pathways can be
activated downstream of IFNAR, including those involving the
phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein
kinases (MAPK), and the CRK adaptor molecules (39, 198). This
leads to the activation of other transcription factors such as IRF,
NF-κB, or PU.1, which contribute to orchestrate cell responses to
the cytokines by regulating both distinct and overlapping sets of
genes as compared to STAT (199, 200).
In summary, IFNAR signals through a remarkable diversity of
pathways, including but not limited to diverse combinations and
kinetics of STAT phosphorylations. This explains at least in part
the diversity of IFN-I effects, including their induction of opposite
responses depending on the physiopathological contexts and/or
the nature of the principal responding cell types (200, 201). IFN-III
induce the same signaling pathways as IFN-I, although they engage
a different heterodimeric receptor, composed of the IL-28RA and
IL-10RB chains and preferentially expressed on epithelial cells
including hepatocytes.
THE DIFFERENT IFN-I SUBTYPES HAVE DIFFERENT AFFINITIES FOR
THEIR RECEPTOR LEADING TO THEIR INDUCTION OF DISTINCT
SIGNALING
In mice and human beings, numerous IFN-I subtypes exist. Func-
tional and population genetic analyses showed that these IFN-I
subtypes significantly differ in their functions (202–207). Hence,
one of most extraordinary feature of IFN-I biology is how IFN-I
subtypes can elicit so many pleiotropic and diverse functions by
interacting with the same receptor complex (208).
Both IFNAR1 and IFNAR2 are required for the initiation of
IFN-I-dependent signals, as mice deficient in either one are highly
susceptible to viral infections (3, 5). The assembling of the IFN-
receptor ternary complex is a two-step process. First, a binary
complex is formed by the binding of one side of the IFN mol-
ecule to IFNAR2. Then, a single binary complex interacts with
IFNAR1 via the other side of the IFN molecule. The stability of
the ternary complex will be determined in part by the associa-
tion and dissociation kinetics between the cytokine and the two
receptor chains, as well as by IFNAR expression levels since the
cell surface concentrations of the receptor subunits are relatively
low. Hence, both the affinity of IFN-I subsets for IFNAR and the
amounts of IFN-I, IFNAR1, and IFNAR2 will regulate their bio-
logical effects (Figure 9A) (209, 210). Cell membrane density of
IFNAR1 and IFNAR2 is also involved in differential IFN-β- ver-
sus IFN-α-induced functional activities, such as anti-proliferative
function (211). A variety of cell-intrinsic parameters can also
impact the lifetime of the IFN-receptor ternary complex, such
as the rate of endocytosis/degradation/recycling of signaling com-
plexes, and negative ISG regulators such as USP18 that decrease
the affinity of IFN-IFNAR1 binding (203, 212).
Based on a definition of a prototypic cytokine-receptor bind-
ing module and by analogy with the EPO receptor system, IFN-I
subtypes were originally postulated to form ternary complexes of
differing architectures, resulting in distinct geometry and assem-
bling of intracellular signaling components (213). Experimental
evidence rejected this hypothesis. Rather, the differential activities
of IFN-I subtypes are determined by the stability of the lig-
and/receptor ternary complex (207, 212). Differential affinities of
the IFN-I subtypes for IFNAR1 and IFNAR2 extracellular domains
generate subtype-specific signaling cascades and biological out-
comes (Figure 9A) (210, 214). Crystal structure of ternary IFN-
I/IFNAR1/IFNAR2 complex illuminated the biochemical com-
plexity of IFN-I interaction with their cognate receptors (215).
The main conformational features of IFN-I/IFNAR1/IFNAR2
ternary complexes are conserved among the different IFN-I, but
are quite different from the other cytokine receptors (214, 215).
In the formation of the binary IFN-I/IFNAR2 complex, IFN-
I ligand discrimination resides on differential energetics during
the interaction of anchor points with IFNAR2, shared by all
IFN-I, as well as on key amino acid substitution among IFN-
I subtypes (215). IFNAR1 then performs major conformational
changes to interact with IFN-I associated in the binary com-
plex, thus displaying an optimized functional plasticity (215).
These differences in the chemistry of IFN-I subtype interaction
with IFNAR2 and IFNAR1 thus explain the different affinities of
IFN-α versus IFN-β within ternary complex and their differential
activities (210).
CELL-INTRINSIC RESPONSES OF DISTINCT CELL TYPES
DIFFERENTIALLY CONTRIBUTE TO IFN-I EFFECTS IN VARIOUS
PHYSIOPATHOLOGICAL CONDITIONS
The functions regulated by IFN-I strongly depend on the main
responding cell types (Figure 9B). This has been studied in vitro
by examining the functional consequences of the stimulation of
different cell types with IFN-I, and in vivo by determining the con-
tribution of cell-intrinsic IFN-I responses of different cell types
to resistance or susceptibility to various diseases. An emerging
concept is the central role of DC responses to IFN-I for induc-
tion of protective immunity against viral infections or tumors
(Figure 3). The development of mutant mice allowing condi-
tional genetic inactivation of Ifnar1 in a cell-type specific manner
using the Cre-lox system (216) has been instrumental in accel-
erating our understanding of how different cell types respond to
IFN-I in vivo and what their respective contribution is to pro-
tective or deleterious IFN-I responses. This has been investigated
most extensively in viral infections (106, 111, 112, 115, 217) but
also in cancer (97, 98), bacterial infections (218), autoimmunity
(216, 219), sepsis (220), or inflammatory diseases (221). Efforts
are being pursued to better understand which cell types respond
to IFN-I in a manner promoting protective versus deleterious
effects in different physiopathological settings. That knowledge
will considerably help to develop novel strategies to modulate IFN-
I functions for promoting health over disease. The development
of mutant mice allowing conditional genetic inactivation of Stat1,
Stat3, and Stat5 (222–226) will help better understanding how
different signaling pathways in different cell types determine the
outcome of IFN-I response in vivo in various conditions. This
knowledge might lead to the development of strategies aiming
at targeting a given cell type with a specific subset of IFN-I, or
in the presence of antagonists of certain signaling pathways, to
surgically tune IFN-I responses in vivo toward the most desirable
outcome.
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FIGURE 9 | Schematic illustration of different mechanisms controlling
the diversity of IFN-I effects. Different parameters that contribute to
promote and control the diversity of IFN-I responses are depicted on the left
side of the figure. References of papers illustrating each mechanism are given
on the right side of the figure. (A) Avidity (a combination of affinity and dose).
For example, the affinity of IFN-β for IFNAR1 is 100-times higher than that of
IFN-α2, and IFNβ is much more potent in inhibiting cellular proliferation or
(Continued )
www.frontiersin.org October 2014 | Volume 5 | Article 526 | 17
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tomasello et al. Designing cell type-targeted IFN-I therapies
FIGURE 9 | Continued
monocyte differentiation into osteoclasts (response A), while both IFN-I
subtypes are equipotent in establishing an anti-viral state (response B). The
same subset of IFN-I can also exert different biological effects at low versus
high doses. For example, low, but not high, doses of IFN-β protect BALB/c
mice from progressive cutaneous and fatal visceral disease after Leishmania
major infection. (B) Cell type specificity. Mouse DC but not NK cells are
strong responders to IFN-I, and cell-intrinsic responses to IFN-I are critical in
DC but not in some other cell types for immune defenses against viral
infections or tumors. (C) Tissue microenvironment. The response of a given
cell type to a given dose of a specific subset of IFN-I can also be modulated
by the microenvironment of the cell. For example, in cancer, protective IFN-I
effects on infiltrating DC or other immune cells might be dampened by
inhibitors of IFNAR signaling locally produced by the tumor, such as ligands of
the TAM receptor tyrosine kinases. (D) Timing. Differences in the time and
duration of exposure to IFN-I can also determine distinct functional outcomes.
For example, during viral infections, early and transient high levels of IFN-I
promote protective DC and T cell responses, while delayed, chronic and low
level IFN-I production compromises host immune defenses and promotes
chronic viral infections. Within a given cell type, the outcome of IFN-I
stimulation also depends on time of exposure to these cytokines relative to
other modulatory signals (timing relative to other stimuli). For example, in
naïve CD8 T cells, TCR signaling prior to IFN-I stimulation leads to increased
expression of STAT4 and promotes IFN-γ production and proliferation, while
IFN-I stimulation prior to TCR triggering leads to STAT1-dependent
anti-proliferative and pro-apoptotic effects.
THE ANATOMICAL LOCATION AND TIMING OF CELL EXPOSURE TO IFN-I
MIGHT ALSO BE MAJOR PARAMETERS CONTROLLING THE EFFECTS OF
THE CYTOKINES
The formation of specific STAT complexes is a highly dynamic
process. It depends not only on the cell type but also on its specific
state at the time it sees IFN-I. Hence, major parameters con-
trolling the effects of IFN-I in a given cell type also include its
microenvironment (Figure 9C) and the timing of its exposure to
the cytokines both in terms of duration of the stimulation and of
previous activation history (Figure 9D).
The TAM receptor ligand Gas6 is expressed within tumor cells
in various solid cancers (227, 228). Elevated Gas6 expression is of
bad prognosis in different cancers (228, 229). In a mouse model
of ovarian cancer, early during tumorigenesis tumor-infiltrating
DCs were found to be immunogenic and promote antitumor
immunity, but they were later altered in the course of tumor devel-
opment to acquire immunosuppressive properties beneficial to
the tumor (230). One may thus hypothesize that expression of
TAM soluble ligands in certain tumors and of TAM receptors on
tumor-infiltrating DCs might contribute to dampen DC response
to IFN-I and therefore facilitate their polarization by the tumor
microenvironment into immunosuppressive cells (Figure 9C).
Acute versus chronic exposure to IFN-I can lead to strikingly
opposite effects on a given cell type (13, 14, 231). In addition
to duration, the time when a cell is exposed to IFN-I can also
dramatically impact its functional response, depending on its pre-
vious activation history (Figure 9D). In vitro stimulation of DCs
with IFN-β can lead to opposite outcomes depending whether
it occurs simultaneously to, or after, TNFα-induced maturation.
IFN-β polarizes DCs toward Th1 induction in the former case, and
toward IL-10-secreting T cells in the latter case. These opposite
effects result at least in part from the differential expression of IL-
12/18 by DCs (232). Similarly, IFN-I effect on the functional polar-
ization of CD4 T cells is strongly modulated by the other cytokines
present in the lymphocyte microenvironment at the same time
(233). IFN-I can also mediate opposite effects on CD8 T cells
depending whether it occurs before or after cognate engagement of
the T cell receptor. Indeed, while CD8 T cells have the potential to
respond to IFN-I by inducing both STAT1- and STAT4-dependent
genes, this depends upon their activation history. Naïve CD8 T cells
respond mostly to IFN-I through STAT1 signaling, leading to the
inhibition of their proliferation and eventually to the induction of
their apoptosis. However, cognate triggering of the T cell receptor
causes a decrease in STAT1 and an increase in STAT4 expression
in CD8 T cells. This leads to a shift of their IFN-I response from
STAT1-to-STAT4 signaling, resulting in the promotion of their
proliferation and IFN-γ production. During LCMV infection, this
mechanism promotes STAT4-dependant expansion of anti-viral
CD8 T cells, but STAT1-dependant inhibition of naïve CD8 T cell
proliferation (234).
INNOVATIVE BIOCHEMICAL ENGINEERING APPROACHES TO
TUNE IFN-I EFFECTS
Since the late 70s the clinical potential of IFN-I for the treatment
of patients suffering of viral infection or cancer diseases has been
widely acknowledged (235). Today, this expectation is tempered
because IFN-I treatment can induce severe side effects and suffi-
cient doses cannot be administered in patients. Therefore, there
is a strong need to create tuned IFN molecules devoid of side
effects. Based on our current understanding of IFN-I responses
as reviewed above, many parameters could be tuned individually
or in a combined manner to modulate IFN-I activity to promote
their beneficial effects over the deleterious ones in a number of
diseases. These parameters include modifying the affinity of IFN-I
for its receptor, playing with the local quantity/concentration of
IFN-I and with the duration of its delivery, and modulating the
nature of the cells that are responding to IFN-I. We will discuss here
novel strategies being developed to deliver IFN-I to, or block IFN-I
responsiveness of, a specific target cell type in vivo (Figure 10).
MODULATING IFN-I FUNCTIONS BY ALTERING THEIR BINDING TO
THEIR RECEPTOR THROUGH ADVANCED BIOCHEMICAL ENGINEERING
If IFN-I-induced side effects are a consequence of the pleiotropic
nature of IFN-I, and if the bioactivities mediating deleterious
effects have some degree of independence from those mediating
beneficial effects, one could mutate the IFN-I molecules in order
to skew their activity toward a desired bioactivity. Indeed, intro-
ducing key mutation in IFN-α2 allowed increasing its affinity to
IFNAR1 by a factor of 100. Accordingly, this IFN-α2 mutant is 100-
times more potent in inhibiting cell proliferation, but as potent as
WT IFN-α2 in inducing an anti-viral state (236–238). Hence, it is
possible to tune IFN activity by modifying its binding to IFNAR.
However, translating such an approach for the design of molecules
for clinical application is severely hampered by the poor under-
standing we have on the IFN-I bioactivities mediating the side
effects. Furthermore, we are far from having established the list of
bioactivities that could be differentially modulated by changing the
stability of the IFN-I/IFNAR complex. We know more about the
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FIGURE 10 | Strategy for high efficiency cell type-specific targeting of
cytokine activity. (A) Most cytokines have evolved to exhibit optimized
specific activities. (B) When the antibody moiety of a classical
immunocytokine binds its cellular target, the ensuing increase of
cytokine-receptor avidity translates into a modest increase of cytokine
potency. (C,D) By introducing a mutation that decreases the affinity of the
cytokine for its receptor, the activity of the mutated immunocytokine is now
focused with a very high efficiency on target cells.
cell types that mediate beneficial versus deleterious IFN responses
in various diseases. Hence, we will now discuss strategies aimed at
focusing IFN activity to specific cell types to promote health over
disease.
CELL SPECIFIC TARGETING OF EXOGENOUS IFN-I
Several strategies have been developed to specifically target IFNs
on tumor cells, tumor-infiltrated immune cells or infected tis-
sues. These strategies include intra-lesional injection (239, 240),
adenoviral-mediated gene transfer (241–243), engineered tumor-
infiltrating monocytes (244), and fusion of IFNs with a cleavable
protecting shell (245). Another strategy to increase cytokine accu-
mulation within the tumor or infected tissue is antibody-mediated
targeting of cytokine delivery, where a cytokine moiety is fused
to an antibody directed against a specific cell surface marker
(Figure 10). The fusion molecule retains both antigen-binding
and IFN-I bioactivities, and is enriched at the targeted site upon
in vivo injection (246–249). When targeted to human CD20, IFN-I
inhibited the proliferation of lymphoma cells engrafted in immun-
odeficient mice (250). An IFN-I targeted to a tumor antigen can
also amplify the therapeutic effect of the antibody by acting on
tumor-infiltrated DCs, thus increasing antigen cross-presentation
and antitumor cytotoxic T cell responses (249). On non-targeted
cells, the antibody conjugation negatively impacts IFN-I potency,
but only modestly (18, 248, 251) (Figure 10A). Fusion molecules
generally retain full IFN-I biological activity on the cells expressing
the antibody target (Figure 10B). Hence, this difference only leads
to a modest ratio between the IFN-I specific activity measured on
target and non-target cells (Figure 10B). Such a targeting efficiency
is definitely too low to reduce the toxic effect of IFN-I adminis-
tration, because it will not specifically focus IFN-I activities on
“beneficial cells” without stimulating “deleterious cells.”
The engineering of immuno-IFN-I must be improved to reach
the very high targeting efficacy required to significantly dimin-
ish the treatment side effects. We recently reported an innovative
strategy reaching this goal (18). It is based on the postulate
that the antibody moiety of an immuno-IFN-I stabilizes the
IFN-I/receptor-complex by avidity. It also takes into account the
fact that the biological potency of an IFN-I is proportional to the
stability of the IFN-I/receptor complex up to a certain threshold
beyond which increasing the stability does not increase its potency
(238, 252). IFN-α2 and IFN-β are used in most immuno-IFN-I
studies. They have evolved to retain close to maximal potency.
Hence, their targeting by an antibody that only provides a modest
gain in terms of biological potency. However, it is expected that
decreasing the affinity of the IFN-I for its receptor, by introducing
a mutation, would increase the targeting effect of the antibody
(Figures 10 C,D). This is indeed the case. Using an IFN-I with a
single point mutation that dramatically decreases its affinity for
IFNAR2 (Figure 10C) allows engineering immuno-IFNs that are
up to 1000-fold more potent on cells expressing the antibody tar-
get (Figure 10D). The three log targeting efficiency of these novel
types of immuno-IFNs is found for various activities measured
in vitro or in vivo when delivered in mice. If the toxic side effect
experienced by the patients treated with IFN-I is due to systemic
IFN-I activity, this targeting technology may find considerable
clinical applications since such engineered immuno-IFNs are vir-
tually inactive while “en route” and are activated only after binding
of the fused antibody to the desired target. It remains to define
the useful targets according to pathologies, for example, tumor
cells themselves and professional cross-presenting XCR1+ DCs
for cancer (97, 98, 249), or hepatocytes for chronic HCV infection.
CELL SPECIFIC BLOCKADE OF ENDOGENOUS IFN-I
To treat autoimmune diseases, novel therapeutics targeting IFN-I
have been developed, including two IFN-α-neutralizing mono-
clonal antibodies currently in clinical trials (Sifalimumab and
Rontalizumab) (253, 254). However, long-term systemic neu-
tralization of IFN-I activity may increase susceptibility to viral
infection and tumor development. Alternative strategies are
needed to specifically inhibit IFN-I deleterious effects in these
diseases without globally compromising IFN-I anti-viral and
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anti-tumoral functions. The sequential nature of the assembling
of the IFN-I/receptor complex opens the possibility to design IFN-
I antagonists specifically targeting the cell subsets responsible for
IFN-I deleterious effects.
An IFN-α2 carrying a single amino acid substitution that blocks
the IFN-I/IFNAR1 interaction engages IFNAR2 in a complex,
which cannot bind IFNAR1 (255). Since the binary IFN-I/IFNAR2
complex is devoid of any IFN-I activity, such mutant behaves as a
potent IFN-I antagonist. When linked to an antibody specific for
a cell surface marker, the antagonistic activity of the mutant IFN-I
should be significantly reinforced specifically on the cells express-
ing the target. Hence, it should be possible to design and construct
targeted antagonists that inhibit responsiveness to endogenous
IFN-I specifically on the cell subsets on which the cytokines act
to promote autoimmunity or severe side effects, leaving the other
cells fully responsive. For example, in chronic HCV patients treated
with Peg-IFN-α, one of the most deleterious side effects is nervous
depression, which might be prevented by co-administration of an
IFN-I antagonist specifically targeting neurons or other cells of the
central nervous system.
CONCLUSION
In the last decade, several major technological breakthroughs and
the generation of novel animal models have remarkably advanced
our understanding of the mode of action of IFNs. In vitro high
throughput screening allowed systematically studying the func-
tions of ISGs by ectopic expression or knock-down. Advance
biophysical investigation of the interactions between IFN-I and
the IFN-I receptor allowed to rigorously investigate the mechanis-
tic basis for the differential bioactivities of IFN-I subtypes. The
analyses of the responses of different cell types to IFNs or to viral
infection, in vitro but also in vivo in various pathologies, demon-
strated that IFN-I often mediate beneficial versus deleterious roles
by acting on different cell types. From integrative analysis of these
data, a picture is now emerging suggesting that it will be possible
to segregate protective from deleterious IFN-I effects, based (i) on
their differential induction depending on IFN-I subsets or on the
magnitude/timing of IFN-I production, (ii) on their condition-
ing in different tissues, (iii) or on their occurrence in different cell
types. Hence, innovative immunotherapeutic treatments are being
designed to tune IFN-I activity toward desired effects in order to
promote health over disease in a manner adapted to each phys-
iopathological condition. In particular, a proof-of-concept has
been made in vitro that it will be possible to target IFN-I activity
on given cell types or tissues to administer to patients sufficiently
high doses of the cytokine at the site of interest while limiting
unwanted effects in other tissues or cell types. The next steps will be
to demonstrate efficacy of this strategy in vivo in preclinical animal
models. Importantly, to foster the development of these innovative
immunotherapies, major efforts are still warranted to continue
delineating which cell types are mainly responsible for the pro-
tective versus deleterious effects of IFN-I in different diseases.
Combining high throughput technologies and systems biology
approaches will also advance our understanding of the molecu-
lar mechanisms dynamically controlling IFN-I responses in health
and diseases, which should reveal potentially novel therapeutic
targets.
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